Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Upgraded by Wall Street Zen to “Sell” Rating

Wall Street Zen upgraded shares of Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) from a strong sell rating to a sell rating in a research report sent to investors on Saturday morning.

Other equities research analysts also recently issued research reports about the company. Stifel Nicolaus dropped their target price on Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating for the company in a research report on Monday, May 11th. Mizuho decreased their price target on Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Weiss Ratings upgraded Senseonics Holdings, Inc. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Finally, HC Wainwright lowered their price objective on Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Senseonics Holdings, Inc. Common Stock presently has a consensus rating of “Moderate Buy” and an average target price of $17.20.

Senseonics Holdings, Inc. Common Stock Price Performance

SENS opened at $7.02 on Friday. Senseonics Holdings, Inc. Common Stock has a one year low of $4.79 and a one year high of $11.58. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.51 and a quick ratio of 3.19. The firm’s 50 day moving average is $5.85. The company has a market capitalization of $293.44 million, a PE ratio of -3.15 and a beta of 1.01.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.08). Senseonics Holdings, Inc. Common Stock had a negative return on equity of 189.06% and a negative net margin of 225.09%.The company had revenue of $14.48 million during the quarter. As a group, analysts anticipate that Senseonics Holdings, Inc. Common Stock will post -2.38 EPS for the current year.

Insider Buying and Selling

In other Senseonics Holdings, Inc. Common Stock news, Director Douglas A. Roeder bought 22,686 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was bought at an average price of $5.56 per share, for a total transaction of $126,134.16. Following the transaction, the director owned 144,635 shares of the company’s stock, valued at approximately $804,170.60. The trade was a 18.60% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. J.Safra Asset Management Corp bought a new stake in Senseonics Holdings, Inc. Common Stock in the second quarter valued at about $636,000. Kestra Advisory Services LLC bought a new position in Senseonics Holdings, Inc. Common Stock during the first quarter worth about $68,000. GSK plc acquired a new position in shares of Senseonics Holdings, Inc. Common Stock during the 4th quarter worth about $60,000. State of Wyoming acquired a new position in shares of Senseonics Holdings, Inc. Common Stock during the 2nd quarter worth about $67,000. Finally, Cetera Investment Advisers bought a new stake in shares of Senseonics Holdings, Inc. Common Stock in the 1st quarter valued at about $85,000. 12.36% of the stock is currently owned by institutional investors.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.